{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"JYP0322","nct_id":"NCT06128148","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=jyp0322-nct06128148. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"JYP0322","arms":[{"description":"Participants with ROS1 fusion-positive locally advanced or metastatic solid tumors will receive JYP0322 at a dose of 50 mg qd. This arm evaluates the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of this dose level.","label":"50 mg qd","type":"EXPERIMENTAL"},{"description":"Participants with ROS1 fusion-positive locally advanced or metastatic solid tumors will receive JYP0322 at a dose of 100 mg qd. This arm assesses safety, tolerability, and pharmacokinetics (PK) data for this dose level.","label":"100 mg qd","type":"EXPERIMENTAL"},{"description":"Participants with ROS1 fusion-positive locally advanced or metastatic solid tumors will receive JYP0322 at a dose of 200 mg qd. This arm examines the safety, pharmacokinetics (PK), and preliminary efficacy of this dose level.","label":"200 mg qd","type":"EXPERIMENTAL"},{"description":"Participants with ROS1 fusion-positive locally advanced or metastatic solid tumors will receive JYP0322 at a dose of 100 mg bid. The arm evaluates the safety, tolerability, and pharmacokinetics (PK) of this increased dosing frequency.","label":"100 mg bid","type":"EXPERIMENTAL"},{"description":"Participants with ROS1 fusion-positive locally advanced or metastatic solid tumors will receive JYP0322 at a dose of 150 mg bid. This arm aims to determine the optimal dosing for safety, pharmacokinetics (PK), and efficacy.","label":"150 mg bid","type":"EXPERIMENTAL"},{"description":"Participants with ROS1 fusion-positive locally advanced or metastatic solid tumors will receive JYP0322 at a dose of 200 mg bid. This arm focuses on evaluating safety, tolerability, and pharmacokinetics (PK) at this dose.","label":"200 mg bid","type":"EXPERIMENTAL"},{"description":"Participants with ROS1 fusion-positive locally advanced or metastatic solid tumors will receive JYP0322 at a dose of 150 mg tid. This arm focuses on evaluating safety, tolerability, and pharmacokinetics (PK) at this dose.","label":"150 mg tid","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-12-30","type":"ESTIMATED"},"conditions":["Protein Kinase Inhibitors","Other Protocol Specified Criteria","Lung Neoplasms","Brain Neoplasms"],"enrollment":{"count":101,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"JYP0322 50 mg qd","otherNames":[],"type":"DRUG"},{"name":"JYP0322 100 mg qd","otherNames":[],"type":"DRUG"},{"name":"JYP0322 200 mg qd","otherNames":[],"type":"DRUG"},{"name":"JYP0322 100 mg bid","otherNames":[],"type":"DRUG"},{"name":"JYP0322 150 mg bid","otherNames":[],"type":"DRUG"},{"name":"JYP0322 200 mg bid","otherNames":[],"type":"DRUG"},{"name":"JYP0322 150mg tid","otherNames":[],"type":"DRUG"}],"last_update":"2025-07-14","lead_sponsor":"Guangzhou JOYO Pharma Co., Ltd","official_title":"A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of JYP0322 in Patients With Solid Tumors","overall_status":"RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2026-06-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"The frequency and severity of adverse events of JYP0322","timeFrame":"From the date of informed consent through 30 days after the last dose of study drug, approximately up to 36 months."}],"references":[],"start_date":{"date":"2022-05-04","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Phase I Study of JYP0322 in ROS1 Fusion-Positive Solid Tumors","url":"https://clinicaltrials.gov/study/NCT06128148"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/jyp0322-nct06128148"}